Keyphrases
Cryptosporidium
100%
Mycobacterium Tuberculosis (M. tb)
66%
Gut Metabolism
50%
Cytotoxicity Profile
50%
Liver Metabolism
50%
Spirocycles
50%
Anti-infective Agents
50%
Infectious Diseases
50%
MmpL3 Inhibitor
50%
Disease Treatment
50%
Therapeutic Agents
50%
Oral Bioavailability
50%
Pks13
50%
Clinical Targets
50%
Cre Recombinase
50%
Ether
50%
Thioesterase
50%
Benzofuran
50%
Preclinical Candidate
50%
Gene Profile
50%
Anti-tuberculosis
50%
Anticryptosporidial
50%
LysR Family
50%
Efficacy in Vivo
50%
Lipophilic
37%
MmpL3
37%
Physicochemical Properties
37%
Cytochrome P450 1A1 (CYP1A1)
33%
Oxidative Metabolism
33%
HERG
33%
Liver
33%
Tuberculosis Infection
25%
Amines
25%
Phenotypic Screening
25%
Calf Model
25%
Nitazoxanide
25%
Compound Properties
25%
Potential Treatments
25%
Neglected Infectious Diseases
25%
Gastrointestinal Infection
25%
Infection Model
25%
Lack of Understanding
25%
Immunodeficient Mice
25%
Unmet Medical Need
25%
Leading Causes of Death
25%
Knowledge Gaps
25%
Preclinical Safety Studies
25%
Mouse Infection
25%
Cryptosporidiosis
25%
Clinical High Risk
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cryptosporidium
75%
Diseases
75%
Cytotoxicity
66%
Infection
50%
Antiinfective Agent
50%
Mycobacterium Tuberculosis
50%
Cre Recombinase
50%
Ion Channel
50%
Bioavailability
50%
Lysine Transfer RNA Ligase
50%
Pharmacokinetics
29%
Zwitterion
25%
Isotopes of Potassium
25%
Pyrazole
25%
Mouse Model
25%
Nelfinavir
16%
Paroxetine
16%
Methylcholanthrene
16%
Cytochrome P450
16%
Cytochrome P450 Reductase
16%
Unspecific Monooxygenase
16%
Oxidoreductase
16%
Combination Therapy
16%
Midazolam
16%
Gastrointestinal Infection
12%
Cryptosporidiosis
12%
Nitazoxanide
12%
